Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06612580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

Name: 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study — clinical trial record (NCT06612580)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseEarly Phase 1

SponsorFirst Affiliated Hospital of Fujian Medical University

Started2024-09-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated September 25, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.

First Affiliated Hospital of Fujian Medical University

56 trials monitored

See all monitored trials

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.

Trial Details

NCT Number	NCT06612580
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Prostate Cancer (Adenocarcinoma)
Enrollment	10 participants
Start Date	2024-09-01
Primary Completion	2025-08-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-09-25